A small pilot finds curcumin lowers HbA1c in prediabetic older adults, but without changing weight, lipids, or overall gut microbiome diversity. PICO summary and commentary.
Browsing: Metabolism
Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
A single-centre randomised controlled trial testing multidisciplinary multifactorial care against standard care in 192 adults with type 2 diabetes, with a modest HbA1c reduction and improved eGFR. PICO summary and expert commentary.
A crossover trial finds orange juice with breakfast raises glucose no more than whole orange or a sugary drink of matched sugar in well-controlled type 2 diabetes. PICO summary and commentary.
An ACCORD analysis finds a triglyceride-glucose-waist index independently predicts cardiovascular events and mortality in type 2 diabetes, beating TyG alone. PICO summary and commentary.
In a phase 2 trial, the antisense DGAT2 inhibitor ION224 met the primary histological endpoint in MASH with fibrosis at week 51, though benefit remains preliminary and per-protocol. PICO summary and expert commentary.
A post-hoc analysis finds exenatide does not change inflammatory or metabolic biomarkers in alcohol use disorder, despite raised baseline inflammation. PICO summary and commentary.
Summary: In patients with type 2 diabetes mellitus (T2DM), Ebenatide treatment significantly improved glycemic control (HbA1c, TIR, TyG), reduced body…
First-in-human phase 1 trial finds the oral GLP-1/amylin co-agonist amycretin safe and well tolerated with dose-dependent gastrointestinal effects; weight and glucose changes were exploratory only. PICO summary and expert commentary.
An early-phase trial reports large but exploratory weight-loss signals for subcutaneous amycretin in overweight and obesity, with safety as the primary focus. PICO summary and expert commentary.
An Eli Lilly-sponsored indirect treatment comparison links tirzepatide 10 and 15 mg to greater weight, BMI and HbA1c reductions than semaglutide 2.4 mg in patients with type 2 diabetes, with no head-to-head trial. PICO summary and expert commentary.